Merck Foundation Announces Alliance for Equity in Cancer Care
The $20 million, five-year-initiative will work to increase equity in U.S. cancer care.
The Merck Foundation (the Foundation) announced today the launch of the Alliance for Equity in Cancer Care (the Alliance), a $20 million, five-year initiative, designed to make cancer care more equitable in the United States by helping patients living in underserved communities receive timely access to high-quality, culturally responsive care.
As part of the initiative, the Foundation is providing grants to select non-profit health care organizations to help develop and implement evidence-informed, innovative programs that advance equity in cancer care.
Grantees will work collectively to improve the coordination of patient care from diagnosis through survivorship; strengthen patient engagement in treatment decisions and overall patient-provider communication; build community partnerships that address barriers to care related to social determinants of health; and provide essential psychosocial support services.
Continue reading here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
